(509) 228-1000 WA
(208) 754-3100 ID

Coronavirus (COVID-19) Update: Get the latest information on how we’re responding to the novel coronavirus (COVID-19). CLICK HERE »

Jessica Hellyer, MD


back to doctors


Medical Oncology and Hematology



Additional Areas of Expertise:

Lung Cancer

Dr. Hellyer graduated magna cum laude from Colorado College with a degree in biochemistry. She went on to attend medical school at University of Colorado where she graduated with honors as a member of the Alpha Omega Alpha honor society. She completed internal medicine residency and subspecialty training in medical oncology at Stanford Hospital in Palo Alto.
During her medical oncology training Dr. Hellyer developed expertise in the treatment of lung cancer, including non-small cell and small cell lung cancers, mesothelioma, and thymic malignancies. She believes in tailoring treatment to each patient and using genetic data from patients’ tumors to help guide treatment. Dr. Hellyer is passionate about improving the lives of patients and advancing the field of oncology through clinical research. She has conducted extensive research into the molecular drivers of lung cancer and the ways in which this information can be used to improve and personalize treatment for patients living with lung cancer.
In her free time, Dr. Hellyer enjoys spending time with her husband and family and exploring the Inland Northwest.

Medical School:

  • University of Colorado School of Medicine; Aurora, CO


  • Stanford University School of Medicine (Internal Medicine); Stanford, CA


  • Stanford University School of Medicine (Medical Oncology); Stanford, CA

  • American Board of Internal Medicine: Internal Medicine, Medical Oncology 


Honors / Leadership
  • Fellowship Scientific Merit Award, Stanford University School of Medicine (2020)
  • MS2 Academic Excellence Award, University of Colorado School of Medicine (2011)
  • MS2 Academic Excellence Award, University of Colorado School of Medicine (2010)
  • Outstanding Research Award, University of Colorado School of Medicine (2010)
  • SOM Research Track Scholar, University of Colorado (2009-2013)

  • Stanford Society for Physician Scholars (2015)
  • Alpha Omega Alpha Medical Honors Society (2014)
  • Phi Beta Kappa (2009)
Textbook Chapters

Hann C, Scherpereel A, Hellyer JA and Wakelee HA. Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors and Mesothelioma. American Society of Clinical Oncology Educational Book 2019 :39, 543-552.

Hellyer JA and Wakelee HA. Lung Cancer in People who have Never Smoked. Caring Ambassadors Lung Cancer Choices. 4th edition. 2019.


Peer-Reviewed Articles

Hellyer JA et al. Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. J Thorac Oncol. 2021.

Aredo JV, Mambetsariev I, Hellyer JA et al. Durvalumab for Stage III EGFR-Mutated NSCLC after Definitive Chemoradiotherapy. J Thorac Oncol. 2021.

Foggetti G, Li C, Cai H, Hellyer JA et al. Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo. Cancer Discovery. 2021.

Hellyer JA et al. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. J Thorac Oncol. 2021;16(3):395-403.

Hellyer JA et al. Everolimus in the treatment of metastatic thymic epithelial tumors. Lung Cancer. 2020;149:97-102.

Hellyer JA and Wakelee HA. Adjuvant Chemotherapy. Thoracic Surgery Clinics. 2020;30(2):179-185.

Hellyer JA and Wakelee HA. Role of Immunotherapy in Stage III Unresectable NSCLC. ASCO Daily News. 5.13.2020.

Jeong Y*, Hellyer JA*, Stehr H, et al. Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients. Clin Can Research. 2020;26(1):274-281.*co-first authors

Hellyer JA, Padda SK, Burns M, et al. Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer. 2019;137:71-75.

Hellyer JA, Stehr H, Das M, et al. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated Non-Small Cell Lung Cancer. Lung Cancer. 2019;134:42-45.

Hellyer JA and Patel MI. Sex disparities in lung cancer incidence: validation of a long observed trend. Transl Lung Cancer Res. 2019;8(4):543-545.

Hellyer J and Wakelee H. Adjuvant PD-(L)1 Checkpoint Inhibitors. IASLC 2019 World Conference on Lung Cancer, 2019: 138-139.

Hellyer JA, Wakelee HA, Badve SS and Padda SK. Harnessing the power of multi-institutional databases to improve the understanding and treatment of thymic epithelial tumors. Mediastinum 2018, 2:61.

Hellyer JA, Padda SK and Wakelee HA. Pembrolizumab in patients with thymic carcinoma: a cautionary tale. Mediastinum 2018, 2:55.

Telli ML, Hellyer J, Audeh W, et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat. 2018;168(3):625-630.

Hellyer JA, Azarbal F, Than CT, Fan J, Schmitt SK, Yang F, Frayne SM, Phibbs CS, Yong C, Heidenreich PA and Turakhia MP. Impact of Baseline Stroke Risk and Bleeding Risk on INR Control among Patients with Atrial Fibrillation on Warfarin (from the TREAT-AF Study). Am J Cardiol. 2017;119(2):268-274.

Yang F, Hellyer JA, Than Claire, Ulla A, Kaiser D, Heidenreich PA, Hoang DD,Winkelmayer W, Schmitt S, Frayne S, Phibbs CS, Turakhia MP. Warfarin Utilization and Quality of INR Control in Patients with Atrial Fibrillation and Chronic Kidney Disease (from the TREAT-AF Study). Heart. 2017;103:818-826.

Hellyer J, Oliver-Allen H, Shafiq M, Tolani A, Druzin M, Jeng M, Rockson S and Lowsky R. Pregnancy Complicated by Gorham-Stout Disease and Refractory Chylothorax. AJP Rep 2016;6(4):355-358.

Rhee KS, Hsueh CH, Hellyer JA, Park HW, Lee YS, Garlie J, Onkka P, Doytchinova AT, Garner JB, Patel J, Chen LS, Fishbein MC, Everett T 4th, Lin SF, Chen PS. 2014. Cervical vagal nerve stimulation activates the stellate ganglion in ambulatory dogs. Korean Circ J;45(2):149-57.

Hellyer J, Akingba AA, Rhee, KS, Tan, A, Lane KA, Shen C, Patel J, Fishbein MC, Lin SF and Chen, PS. 2014. Autonomic Nerve Activity and Blood Pressure Fluctuation in Ambulatory Dogs. Heart Rhythm;11:307-313.

Onkka P, Maskoun W, Rhee KS, Hellyer J, Patel J, Tan J, Chen LS, Vinters HV, Fishbein MC, Chen PS. Sympathetic nerve fibers and ganglia in canine cervical vagus nerves: Localization and quantitation. Heart Rhythm. 2013;10:585–591.

Hellyer JA, Garrido EF, Petrenko CLM, Taussig HN. Are maternal and community risk factors associated with the presence of asthma among children placed in foster care? Child Youth Serv Rev. 2013;35:129-132.

Moding E, Hellyer J, Rank K, Lostroh P. and Brasuel M. Characterization of PEBBLEs as a Tool for Real-Time Measurement of Dictyostelium discoideum Endosomal pH. Journal of Sensors. 2009.